Back to Search
Start Over
Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19
- Source :
- Journal of Crohn's & Colitis, Journal of Crohns and Colitis
- Publication Year :
- 2020
- Publisher :
- Oxford University Press, 2020.
-
Abstract
- Patients with inflammatory bowel diseases [IBD] are frequently treated with immunosuppressant medications. During the coronavirus disease 2019 [COVID-19] pandemic, recommendations for IBD management have included that patients should stay on their immunosuppressant medications if they are not infected with the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], but to temporarily hold these medications if symptomatic with COVID-19 or asymptomatic but have tested positive for SARS-CoV-2. As more IBD patients are infected globally, it is important to also understand how to manage IBD medications during convalescence while an individual with IBD is recovering from COVID-19. In this review, we address the differences between a test-based versus a symptoms-based strategy as related to COVID-19, and offer recommendations on when it is appropriate to consider restarting IBD therapy in patients testing positive for SARS-CoV-2 or with clinical symptoms consistent with COVID-19. In general, we recommend a symptoms-based approach, due to the current lack of confidence in the accuracy of available testing and the clinical significance of prolonged detection of virus via molecular testing.
- Subjects :
- medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
media_common.quotation_subject
IBD
Pneumonia, Viral
Supplement Articles
Inflammatory bowel disease
Asymptomatic
Risk Assessment
Drug Administration Schedule
Betacoronavirus
Immunocompromised Host
COVID-19 Testing
Internal medicine
Pandemic
medicine
Humans
Clinical significance
Asymptomatic Infections
Pandemics
media_common
AcademicSubjects/MED00260
business.industry
Clinical Laboratory Techniques
SARS-CoV-2
Convalescence
Gastroenterology
COVID-19
immunomodulator
General Medicine
medicine.disease
Inflammatory Bowel Diseases
digestive system diseases
de-escalation
Crohn’s
medicine.symptom
business
Risk assessment
Coronavirus Infections
biologic
De-escalation
Immunosuppressive Agents
Subjects
Details
- Language :
- English
- ISSN :
- 18764479 and 18739946
- Volume :
- 14
- Issue :
- Suppl 3
- Database :
- OpenAIRE
- Journal :
- Journal of Crohn's & Colitis
- Accession number :
- edsair.doi.dedup.....1cc83894df90092fd19d1aa48c40bb2c